Drug Profile
Research programme: influenza vaccines - AstraZeneca/GlaxoSmithKline
Latest Information Update: 06 Aug 2021
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 28 Feb 2011 No development reported - Preclinical for Influenza virus infections in USA (unspecified route)
- 24 Sep 2007 Preclinical trials in Influenza virus infections in USA (unspecified route)